Abstract:Background: This study investigated the feasibility, safety, and efficacy of the intramuscular injection of CD34+ cells isolated from peripheral blood mononuclear cells (PB-MNCs) mobilized by granulocyte colony-stimulating factor (G-CSF) for the management of patients with critical limb ischemia (CLI) who were considered unlikely to have successful long-term revascularization with open bypass or endovascular methods. Cell therapy represents a new treatment modality for this subgroup of patients with CLI. To date, bone marrow or PB-MNCs have usually been used for transplantation. The current pilot study investigated whether the transplantation of purified CD34+ cells only would be competent in ischemia relief and limb salvage.Methods: From May 2009 to July 2011, 25 patients (mean age, 44 +/- 12 years) were enrolled, and 25 lower extremities and three upper extremities were treated. After subcutaneous administration of G-CSF for 5 days at a dose of 5 to 10 mu g/kg, apheresis and immunomagnetic separation were performed to acquire the isolated CD34+ cells, which were then intramuscularly injected into the ischemic sites. The patients were divided into three groups: low-dose, 10(5)/kg; medium-dose, 5 x 10(5)/kg; and high-dose, 10(6)/kg. The overall outcomes among all patients and the comparison among the groups were evaluated.Results: During the follow-up of 6 to 33 months, the overall outcomes showed that the Wong-Baker FACES pain rating scale score (WFPRSS) decreased from 7 +/- 2 to 3 +/- 3 (P < .001) and 1 +/- 2 (P < .001) at 1 and 2 months, respectively; at 3 and 6 months, respectively, the peak pain-free walking time increased from 4 +/- 3 to 13 +/- 7 (P < .001) and 18 +/- 6 minutes (P < .001), the ankle-brachial index increased from 0.46 +/- 0.21 to 0.60 +/- 0.17 (P = .003) and 0.67 +/- 0.15 (P = .001), and the transcutaneous partial oxygen pressure increased from 27 +/- 10 to 41 +/- 11 (P < .001) and 55 +/- 12 mm Hg (P < .001). Ulcers were healed in 10 of the 14 patients; four patients required above-knee or below-knee amputation <= 3 months. The Kaplan-Meier estimate of the rate of freedom from major amputation at 6 months was 84% (95% confidence interval, 63%-94%). The comparison among the three groups (low-dose, 5; medium-dose, 11; high-dose, 9) revealed no significant difference, except that the WFPRSS improvement at 1 month from baseline in the high-dose group (6.3 +/- 1.7) was significantly superior to that in the low-dose (3.2 +/- 3.3; P = .0487) and medium-dose (3.7 +/- 2.8; P = .0352) groups.Conclusions: Transplantation of CD34+ cells isolated from G-CSF-mobilized PB-MNCs appears to be feasible and safe, showing encouraging outcomes in the treatment of CLI patients who appear to have compromised options for long-term revascularization.

Identification of CD141+vasculogenic precursor cells from human bone marrow and their endothelial engagement in the arteriogenesis by co-transplantation with mesenchymal stem cells

Therapeutic Angiogenesis of Bone Marrow Mononuclear Cells (mncs) and Peripheral Blood Mncs: Transplantation for Ischemic Hindlimb

Angiogenic Potential of Canine Bone Marrow Derived Mesenchymal Stem Cells in Ischemic Limb

[Therapeutic Neovascularization with Autologous Bone Marrow CD34+ Cells Transplantation in Hindlimb Ischemia].

Sourcing of human peripheral blood-derived myeloid angiogenic cells under xeno-free conditions for the treatment of critical limb ischemia

Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy

A Combination of Distinct Vascular Stem/Progenitor Cells for Neovascularization and Ischemic Rescue.

Abstract 606: Ischemic Rescue by Transplantation of Vascular Progenitor Cells Isolated from Fat

Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products

Abstract 723: Agonist of Growth Hormone Releasing Hormone Enhances Angiogenic Therapy by Mesenchymal Stem Cells

Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia

Mesenchymal stem cells for critical limb ischemia: their function, mechanism, and therapeutic potential

Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial

Transplantation of Purified CD34+ Cells in the Treatment of Critical Limb Ischemia.

Preclinical Evaluation of Bone Marrow Mesenchymal Stem Cells Overexpressing MicroRNA-126 to Treat Critical Limb Ischemia

Enhancement strategy for effective vascular regeneration following myocardial infarction through a dual stem cell approach

Human Umbilical Cord-Derived Mesenchymal Stem Cells Relieve Hind Limb Ischemia by Promoting Angiogenesis in Mice

Angiogenic Potential of Bone Marrow Derived CD133+ and CD271+ Intramyocardial Stem Cell Trans- Plantation Post MI

Human Stem Cells Overexpressing miR‐21 Promote Angiogenesis in Critical Limb Ischemia by Targeting CHIP to Enhance HIF‐1α Activity

Hyaluronic Acid Facilitates Angiogenesis of Endothelial Colony Forming Cell Combining With Mesenchymal Stem Cell via CD44/ MicroRNA-139-5p Pathway

Current Status of Angiogenic Cell Therapy and Related Strategies Applied in Critical Limb Ischemia